Qubigen and the University of Melbourne Sign Memorandum of Understanding to Explore Drug Development Collaboration

Qubigen is pleased to announce the signing of a Memorandum of Understanding (MoU) with the University of Melbourne, marking the beginning of a potential strategic collaboration for small molecule drug development.

Under this MoU, the parties will explore cooperative research opportunities focused initially on AI-based design of small molecule therapeutics for newly identified protein targets.

The agreement establishes a framework for information sharing and future joint projects between Qubigen and the Department of Infectious Diseases at the Peter Doherty Institute for Infection and Immunity. The intended collaboration will combine the university’s world-class biological and disease-specific expertise with Qubigen’s proprietary AI-driven drug design technologies, including its Federated AI platform, quantum chemistry tools, and virtual screening capabilities. The MoU remains in effect for three years and provides the basis for ongoing research collaboration.

As Qubigen continues to expand its network of research partnerships across academia and industry, this agreement underscores the company's commitment to applying its advanced AI technologies to solve high-impact biological challenges.

Qubigen - accelerate drug design without exposing secrets

Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next discovery.

enquiries@qubigen.com.